查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1832213

抗凝血酶市場按類型、來源、劑型、治療用途和最終用戶分類－2025-2032 年全球預測

Antithrombin Market by Type, Source, Form, Dosage Form, Therapeutic Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年抗凝血酶市場將成長至 10.9515 億美元，複合年成長率為 4.83%。

主要市場統計數據
基準年2024年 7.5049億美元
預計2025年 7.8532億美元
預測年份：2032年 10.9515億美元
複合年成長率（%） 4.83%

全面介紹抗凝血酶生物學、臨床相關性、診斷複雜性、影響現代凝血療法的治療意義。

抗凝血酶作為一種絲胺酸蛋白酶抑制劑，能夠調節凝血酶和Xa因子的活性，在止血過程中發揮核心作用。近幾十年來，其臨床和研究意義顯著擴展。臨床醫師在各種情況下都會遇到抗凝血酶缺乏症，從遺傳性終身疾病到嚴重疾病的後天性缺陷，進而影響治療決策和風險管理策略。從轉化科學的角度來看，抗凝血酶既是重要的生物標記物，也是潛在的治療藥物，而血漿來源抗凝血酶和重組抗凝血酶之間的區別帶來了安全性、免疫抗原性和生產的考慮。

隨著法律規範的不斷發展，診斷演算法正在將抗凝血酶活性檢測與基因和臨床數據相結合，以完善病例定義並指導替代療法。此外，製劑和給藥技術的進步也開始改變抗凝血酶產品的儲存、給藥方式以及在急性和慢性照護中的應用。綜上所述，這些因素使抗凝血酶成為實驗室研究、臨床應用和治療方法創新之間的紐帶，並對醫院、診斷實驗室和尋求最佳化患者預後的研究項目產生深遠影響。

不斷發展的科學、監管和臨床動態正在改變抗凝血酶產品的開發、診斷方法和治療模式

在科學進步、監管壓力和臨床實踐不斷發展的推動下，抗凝血酶領域正在經歷一場變革。重組技術的創新正在減少對血漿來源的依賴，並引發了圍繞生產擴充性、產品一致性和批次間差異性的討論。同時，檢測準確性的提高和照護現場技術的進步使得能夠早期準確地識別抗凝血酶缺乏症，從而影響高風險環境中的預防策略和急性管理。

同時，對抗凝血酶在發炎和內皮生物學中的作用的更清晰理解正在重塑治療模式，鼓勵人們考慮超越經典凝血障礙的更廣泛適應症。監管機構對血漿來源和病原體惰性方法的審查，推動了人們對可追溯性和安全性的期望，而醫療保健系統則將供應鏈彈性和低溫運輸最佳化放在首位。因此，生產、臨床和設施領域的相關人員正在重新調整優先事項，以平衡療效、安全性和營運可行性，這些轉變將影響未來的採購、臨床指南和研發藍圖。

評估 2025 年美國關稅如何重新調整抗凝血酶供應鏈中的供應鏈、採購重點和國內生產策略

美國2025年實施的關稅政策為抗凝血酶生態系統帶來了新的複雜性，影響了整個價值鏈的籌資策略和供應商選擇。進口關稅正在影響製造商在本地化生產、與填充廠合作以及供應鏈路線規劃方面的決策，以降低增加的到岸成本。醫院和大型綜合分銷網路正在透過審查供應商合約、強調多方採購安排和緊急庫存來應對，以維持臨床的連續性。

在下游領域，關稅上調加速了關於國內生產能力以及在境內擴大重組生產規模可行性的討論。同時，診斷和研究實驗室也考慮了與替代採購相關的營運權衡，例如增加的前置作業時間和低溫運輸冗餘的需求。雖然採購團隊承受了眼前的行政負擔，但這種政策環境也鼓勵了對本地製造夥伴關係和流程最佳化計畫的策略性投資，旨在減輕未來外部政策變化的影響。展望未來，相關人員越來越重視有韌性、透明且適應性強的供應框架，以管理貿易政策對抗抗凝血酵素可用性和可靠性的連鎖反應。

詳細的細分洞察，將產品異構體、採購途徑、配方選擇、治療用途和最終用戶需求與臨床採用和開發重點聯繫起來

細分主導分析揭示了不同的產品和最終用戶載體如何影響抗凝血酶的臨床效用、開發選擇和採用動態。按類型分析時，α和BETA異構體之間的區別異構體獨特的生化特性和生理作用，可以為診斷解讀和治療靶點提供資訊，從而影響檢測方法的選擇和治療方案的製定。按來源分析，人類血漿來源抗凝血酶和重組抗凝血酶之間的對比凸顯了供體依賴性、病原體安全性和生產控制方面的權衡，這些權衡通常與機構採購政策和臨床醫生偏好相互交叉。

在考慮製劑形式，液體和粉末配方之間的差異對於臨床儲存、保存期限和重建工作流程非常重要；這些屬性決定了產品如何納入輸液室和急救方案。注射劑和口服混懸液之間的差異決定了給藥途徑和患者依從性，尤其是在門診和家庭輸液環境中。抗凝血酶的治療用途包括後天性缺陷、急性胰臟炎、先天性缺陷、瀰漫性血管內凝血、肝病和與敗血症相關的凝血障礙，每種用途都有其獨特的臨床終點、監測需求和證據層次。最後，門診手術中心、診所、診斷實驗室、醫院和研究機構之間的最終用戶細分凸顯了不同醫療環境中採用該藥物的不同促進因素：醫院強調急性使用和密切監測，診斷實驗室優先考慮檢測可靠性，研究機構強調機制研究和轉化驗證。

全面的區域觀點，說明美洲、歐洲、中東和非洲以及亞太地區的趨勢將如何影響抗凝血酶的生產、監管和臨床獲取

區域動態對抗凝血酶的生產、監管和部署方式有著重大影響，因此了解地理差異對於策略規劃至關重要。在美洲，臨床網路和醫院系統優先考慮快速獲得急性護理，並通常維持複雜的採購通訊協定以平衡價格和供應連續性，而區域法規結構則強調捐贈者的安全和生物製藥的可追溯性。在歐洲、中東和非洲，監管的多樣性和多樣化的醫療保健基礎設施導致了不同的獲取和採用模式，一些市場優先考慮集中採購，而另一些市場則依賴區域夥伴關係關係進行供應和低溫運輸物流。

在全部區域，生物技術製造能力的投資不斷增加，臨床研究也日益加強，這正在重塑供應商的佈局，並增加重組產品的選擇。此外，多個司法管轄區內醫療體系的轉型正在提升診斷能力，以改善抗凝血酶異常的檢測，並為各種治療應用提供證據支持。綜上所述，這些全球趨勢表明，產品策略、監管參與和分銷模式必須根據區域優先事項量身定做，跨境合作和技術轉移仍將是改善全球可及性和臨床療效的重要槓桿。

公司層面的關鍵洞察：製造商​​、生物技術創新者和專業合作夥伴如何透過製造、監管策略和臨床合作實現差異化

抗凝血酶的競爭與合作格局由成熟的生技藥品製造商、新興的生物技術公司以及專業的受託製造廠商組成，每家公司都擁有獨特的能力。一些公司強調血漿衍生專業知識和捐贈者安全系統，而其他公司則大力投資重組表達平台和製程增強技術，以提高產量並降低差異性。臨床研究團隊與製造商之間的策略聯盟正變得越來越普遍，這使得他們能夠加快新適應症的證據生成，並改善上市後監測框架。

此外，與專業物流供應商和診斷公司合作有助於最佳化低溫運輸完整性和檢測標準化，從而支援更安全、更可靠的產品部署。競爭差異化越來越依賴生產穩健性、法規生命週期管理以及為臨床試驗客戶提供全面技術支援的能力。隨著相關人員追求更廣泛的臨床檢驗和標籤擴展可能性，智慧財產權策略、平台技術和生產佈局決策將繼續決定哪些公司能夠引領創新，以及哪些合作聯盟能夠提供集體優勢。

為高階主管領導層提供切實可行的建議，以加強整個抗凝血酶價值鏈的製造彈性、監管參與和臨床採用策略

產業領導者應採取一系列切實可行、影響深遠的行動，以應對科學發展、政策轉變和不斷變化的臨床需求。首先，投資於靈活的生產策略，將重組生產能力與地理分佈的填充能力相結合，以減少對單一來源的依賴，並適應區域採購偏好。其次，優先考慮可靠的分析方法和檢測方法的外部驗證，以提高診斷信心，並支持不同醫療機構的臨床應用。第三，積極與監管機構合作，在可追溯性、病原體安全方法和上市後證據生成方面達成一致，從而促進產品接受度和長期安全監測。

此外，我們將與醫院系統、診斷實驗室和研究機構建立策略夥伴關係，共同設計基於真實世界的實證研究，以證明抗凝血酶在潛在治療應用中的臨床價值。我們將透過多元化物流合作夥伴和投資低溫運輸來增強供應鏈的彈性，同時探索能夠根據政策和需求變化快速擴展的製造外包關係。最後，我們將透過針對臨床醫生和採購團隊的有針對性的培訓來加強商業準備，這些培訓旨在闡明產品差異化、管理工作流程以及供應商和配方選擇對患者管理的影響。

闡明一種混合方法研究方法，將文獻綜合、監管調查、技術評估和專家訪談結合起來，為實際決策提供資訊

本次分析綜合了同行評審文獻、監管文件、臨床試驗註冊中心、產品標籤、生產白皮書以及對臨床醫生、供應鏈專業人員和行業專家的結構化訪談的證據。主要的定性輸入包括測試方法審查以及與藥品附加檔的三角檢驗，以確保全面了解產品特性和臨床工作流程。為了保持調查方法的嚴謹性，我們採用了標準化的臨床試驗評估標準、交叉引用了主要司法管轄區的監管指南，並記錄了每項關鍵聲明的資料來源。

重組和血漿衍生產品的技術評估盡可能以工藝描述和專家關於擴充性和品管的評論為支撐。透過情境分析和相關人員訪談評估供應鏈和政策影響，以了解營運現狀和適應策略。自始至終，該方法都強調透明度、可重複性和對決策者的實際相關性，並在證據不斷發展或臨床共識尚未達成的情況下提出警告。這種混合方法框架確保結論和建議基於多種證據來源，並根據實際營運限制進行量身定做。

結論摘要強調了推動抗凝血酶科學和臨床應用所需的科學創新、營運彈性和策略參與之間的相互作用

總而言之，抗凝血酶是一個多方面的臨床和技術領域，其中科學的細微差別、製造選擇和醫療保健服務的現實情況相互交織。重組技術的發展、精細診斷以及對區域製造的投資正在改變產品的開發、監管和消費方式。同時，由於異構體、來源、劑型、治療用途和最終用戶情況的細分化，凸顯了製定精細客製化的產品和商業化策略的必要性。

要在這種環境下取得成功，相關人員必須在創新與營運信譽之間取得平衡，儘早與監管機構和臨床意見領袖溝通，並使生產佈局與區域可及性需求保持一致。嚴謹的證據生成、策略夥伴關係以及靈活的物流規劃相結合，將使企業能夠有效滿足臨床需求，同時推動抗凝血酶治療和診斷科學的發展。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 重組抗凝血酶治療對降低心血管手術術後血栓症形成風險的影響
  • 評估新興醫療保健市場重組抗凝血酶產品的全球准入壁壘
  • 評估缺陷篩檢計畫對醫療資源利用的經濟影響
  • 加護治療和急診室採用照護現場活動測量的趨勢
  • 重組抗凝血酶藥物跨國臨床試驗的監管協調挑戰
  • SARS-CoV-2 誘發的凝血病對治療需求和定價策略的影響
  • 整合藥物基因組學數據以最佳化血栓症高風險患者的替代劑量
  • 長期安全性和有效性數據將塑造投資者對下一代生物相似藥的信心

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第8章 抗凝血酶市場（按類型）

  • 阿爾法
  • 測試版

9. 抗凝血酶市場（依來源）

  • 人體血漿
  • 重組

第 10 章抗凝血酶市場（依形式）

  • 液體
  • 粉末

第 11 章：抗凝血酶市場（按劑型）

  • 注射
  • 口服懸浮液

第 12 章：抗凝血酶市場（依治療應用）

  • 後天缺陷
  • 急性胰臟炎
  • 出生缺陷
  • 瀰漫性血管內凝血
  • 肝病
  • 膿毒症相關凝血病

第 13 章。抗凝血酶市場（按最終用戶）

  • 門診手術中心
  • 診所
  • 診斷實驗室
  • 醫院
  • 研究機構

第 14 章。按地區分類的抗凝血酶市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第 15 章抗凝血酶市場（按類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 16 章。各國抗凝血酶市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Baxter International Inc.
    • Bio-Techne Corporation
    • Biocon Ltd.
    • Boehringer Ingelheim Pharma GmbH & Co. KG
    • China Biologic Products, Inc.
    • Diapharma Group, Inc.
    • European Medicines Agency
    • F. Hoffmann-La Roche Ltd
    • Genesis BioPharma Services
    • Grifols, SA
    • Jiangsu Hengrui Medicine Co., Ltd.
    • Lee Biosolutions, Inc.
    • LFB USA, Inc.
    • Merck KGaA
    • Novartis AG
    • Octapharma AG
    • Pfizer Inc.
Product Code: MRR-4358BACA8223

The Antithrombin Market is projected to grow by USD 1,095.15 million at a CAGR of 4.83% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 750.49 million
Estimated Year [2025] USD 785.32 million
Forecast Year [2032] USD 1,095.15 million
CAGR (%) 4.83%

Comprehensive introduction to antithrombin biology, clinical relevance, diagnostic complexity, and therapeutic implications shaping contemporary coagulation care

Antithrombin occupies a central role in hemostasis as a serine protease inhibitor that modulates thrombin and factor Xa activity, and its clinical and research significance has expanded markedly over recent decades. Clinicians encounter antithrombin deficiency across a spectrum that ranges from inherited, lifelong disorders to acquired deficiencies in critical illness, which in turn influence therapeutic decision-making and risk management strategies. From a translational science perspective, antithrombin is consequential both as a biomarker and as a therapeutic agent candidate, with distinctions between plasma-derived and recombinant sources shaping safety, immunogenicity, and manufacturing considerations.

As regulatory frameworks evolve, diagnostic algorithms increasingly integrate antithrombin activity assays with genetic and clinical data to refine case definitions and guide replacement therapy. Furthermore, advances in formulation science and delivery modalities have begun to change how antithrombin products are stored, administered, and integrated into acute and chronic care pathways. Taken together, these elements establish antithrombin as a nexus point between laboratory investigation, bedside practice, and therapeutic innovation, with downstream implications for hospitals, diagnostic laboratories, and research programs seeking to optimize patient outcomes.

Evolving scientific, regulatory, and clinical dynamics that are transforming antithrombin product development, diagnostic approaches, and care delivery models

The landscape surrounding antithrombin is undergoing transformative shifts driven by scientific progress, regulatory pressure, and evolving clinical practice. Innovations in recombinant technology have reduced reliance on plasma-derived sources and have catalyzed discussions about manufacturing scalability, product consistency, and batch-to-batch variability. Concurrently, improvements in assay precision and point-of-care diagnostics are enabling earlier and more accurate identification of antithrombin insufficiency, which affects both prophylactic strategies and acute management in high-risk settings.

In parallel, therapeutic paradigms are being reshaped by a clearer understanding of antithrombin's role in inflammation and endothelial biology, prompting investigation into broader indications beyond classical coagulation disorders. Regulatory scrutiny related to plasma sourcing and pathogen inactivation methods has raised expectations for traceability and safety, while health systems emphasize supply chain resilience and cold chain optimization. As a result, stakeholders across production, clinical, and institutional domains are recalibrating priorities to balance efficacy, safety, and operational feasibility, and these shifts will influence procurement, clinical guidelines, and R&D roadmaps going forward.

Assessment of how the 2025 United States tariff measures recalibrated supply chains, procurement priorities, and domestic production strategies in the antithrombin supply network

United States tariff policies implemented in 2025 have introduced a new layer of complexity for the antithrombin ecosystem, affecting procurement strategies and supplier selection across the value chain. The import tariffs have influenced manufacturer decisions regarding localization of production, partnerships for fill-and-finish operations, and supply chain routing to mitigate incremental landed costs. Hospitals and large integrated delivery networks have responded by revisiting supplier contracts, emphasizing multi-sourcing arrangements and contingency inventories to preserve clinical continuity.

In downstream terms, the tariffs have accelerated conversations about domestic capacity and the feasibility of scaling recombinant production within national borders. Simultaneously, diagnostic laboratories and research institutes have weighed the operational trade-offs associated with alternative sourcing, including increased lead times and the potential need for cold chain redundancies. Although procurement teams navigated near-term administrative burdens, the policy environment also catalyzed strategic investments in local manufacturing partnerships and process optimization initiatives aimed at reducing exposure to future external policy shifts. Looking ahead, stakeholders are increasingly prioritizing resilience, transparency, and adaptive supply frameworks to manage the ripple effects of trade policy on antithrombin accessibility and reliability.

Detailed segmentation insights linking product isoforms, sourcing routes, formulation choices, therapeutic uses, and end-user needs to clinical adoption and development priorities

Segmentation-driven analysis reveals how different product and end-user vectors shape clinical utility, development choices, and adoption dynamics for antithrombin. When examined by type, the distinctions between alpha and beta isoforms inform diagnostic interpretation and therapeutic targeting because biochemical properties and physiological roles vary, which can influence assay selection and treatment tailoring. By source, contrasts between human plasma-derived and recombinant antithrombin highlight trade-offs in donor-dependence, pathogen safety, and manufacturing control, and these factors frequently intersect with institutional procurement policies and clinician preferences.

Considering form factors, the distinctions between liquid and powder formulations matter for storage, shelf life, and reconstitution workflows in clinical settings, and these attributes determine how products are integrated into infusion suites and emergency protocols. Dosage form differentiation between injectable preparations and oral suspensions shapes administration pathways and patient adherence considerations, particularly in ambulatory care and home infusion contexts. Across therapeutic applications, antithrombin is applied in acquired deficiency, acute pancreatitis, congenital deficiency, disseminated intravascular coagulation, liver disease, and sepsis associated coagulopathy, each presenting unique clinical endpoints, monitoring demands, and evidence hierarchies. Finally, end-user segmentation encompassing ambulatory surgical centers, clinics, diagnostic laboratories, hospitals, and research institutes underscores that adoption drivers differ by care setting, with hospitals emphasizing acute use and intensive monitoring, diagnostic laboratories prioritizing assay reliability, and research institutes concentrating on mechanistic studies and translational validation.

Comprehensive regional perspective explaining how Americas, Europe Middle East & Africa, and Asia-Pacific trends influence production, regulation, and clinical access for antithrombin

Regional dynamics exert a powerful influence on how antithrombin is produced, regulated, and deployed, and understanding geographic nuances is essential for strategic planning. In the Americas, clinical networks and hospital systems often prioritize rapid access to acute care therapies and maintain complex procurement protocols that balance price with supply continuity, while regional regulatory frameworks emphasize donor safety and biologic traceability. In Europe, Middle East & Africa, regulatory heterogeneity and variable healthcare infrastructures create a spectrum of access and adoption patterns, with some markets emphasizing centralized procurement and others relying on local partnerships to manage supply and cold chain logistics.

Across the Asia-Pacific region, rising investment in biotechnology manufacturing capacity and growing clinical research activity are reshaping supplier footprints and increasing the availability of recombinant options. Transitional healthcare systems in multiple jurisdictions are also expanding diagnostic capabilities, which improves detection of antithrombin abnormalities and supports evidence generation for diverse therapeutic applications. Taken together, these geographic trends suggest that product strategy, regulatory engagement, and distribution models must be tailored to regional priorities, and that cross-border collaboration and technology transfer will remain important levers for improving availability and clinical outcomes globally.

Key company-level insights describing how manufacturers, biotech innovators, and specialized partners differentiate through manufacturing, regulatory strategy, and clinical collaboration

The competitive and collaborative landscape for antithrombin includes a mix of established biologics manufacturers, emerging biotechnology firms, and specialized contract development and manufacturing organizations, each contributing distinct capabilities. Some players emphasize plasma-derived expertise and donor-safety systems, while others have invested heavily in recombinant expression platforms and process intensification techniques to enhance yield and reduce variability. Strategic alliances between clinical research groups and manufacturers have become more prevalent, enabling accelerated evidence generation for novel indications and improved post-market surveillance frameworks.

In addition, partnerships with specialized logistics providers and diagnostic firms are helping to optimize cold chain integrity and assay standardization, which in turn supports safer and more reliable product deployment. Competitive differentiation increasingly rests on a combination of manufacturing robustness, regulatory lifecycle management, and the ability to supply comprehensive technical support to clinical customers. As stakeholders pursue broader clinical validation and potential label expansions, intellectual property strategies, platform technologies, and manufacturing footprint decisions will continue to shape which companies lead in innovation and where collaborative consortia may offer collective advantages.

Actionable recommendations for executives to enhance manufacturing resilience, regulatory engagement, and clinical adoption strategies across the antithrombin value chain

Industry leaders should adopt a set of pragmatic, high-impact actions to navigate scientific developments, policy shifts, and evolving clinical needs. First, invest in flexible manufacturing strategies that combine recombinant production capabilities with geographically distributed fill-and-finish capacity to reduce single-source exposure and to respond to regional procurement preferences. Second, prioritize robust analytical methods and external validation of assays to improve diagnostic confidence and to support clinical adoption across diverse care settings. Third, engage proactively with regulatory authorities to align on traceability, pathogen-safety approaches, and post-market evidence generation that will facilitate product acceptance and long-term safety monitoring.

Additionally, cultivate strategic partnerships with hospital systems, diagnostic laboratories, and research institutes to co-design real-world evidence generation efforts that demonstrate clinical value across the therapeutic applications where antithrombin may be impactful. Strengthen supply chain resiliency by diversifying logistics partners and investing in cold chain redundancy, while also exploring contract manufacturing relationships that can be scaled quickly in response to policy or demand shifts. Finally, enhance commercial readiness through targeted education for clinicians and procurement teams that clarifies product differentiators, administration workflows, and the implications of source and formulation choices for patient management.

Clear explanation of the mixed-methods research approach integrating literature synthesis, regulatory review, technical assessment, and expert interviews to inform practical decision-making

This analysis synthesizes evidence from peer-reviewed literature, regulatory documents, clinical trial registries, product labelling, manufacturing white papers, and structured interviews with clinicians, supply chain professionals, and industry experts. Primary qualitative inputs were triangulated with laboratory method reviews and formulation dossiers to ensure a comprehensive view of product characteristics and clinical workflows. Methodological rigor was maintained by applying standardized appraisal criteria to clinical studies, cross-referencing regulatory guidance across major jurisdictions, and documenting data provenance for each major assertion.

Where possible, technical assessments of recombinant versus plasma-derived production were corroborated with process descriptions and expert commentary on scalability and quality control. Supply chain and policy impacts were evaluated through scenario analysis and stakeholder interviews to capture operational realities and adaptive strategies. Throughout, the approach emphasized transparency, reproducibility, and practical relevance for decision-makers, and caveats were noted where evidence was evolving or where clinical consensus had not yet been established. This mixed-methods framework ensures that conclusions rest on multiple, corroborative lines of evidence and that recommendations are tailored to real-world operational constraints.

Concluding synthesis emphasizing the interplay of scientific innovation, operational resilience, and strategic engagement necessary to advance antithrombin science and clinical access

In conclusion, antithrombin represents a multifaceted clinical and technological domain where scientific nuance, production choices, and healthcare delivery realities intersect. Ongoing advances in recombinant technologies, diagnostic precision, and regional manufacturing investments are changing how products are developed, regulated, and consumed. Trade policy developments have underscored the importance of supply chain resilience and local capacity, while segmentation across isoform, source, form, dosage form, therapeutic application, and end-user context highlights the need for finely calibrated product and commercialization strategies.

To succeed in this environment, stakeholders must balance innovation with operational reliability, engage early with regulators and clinical opinion leaders, and align manufacturing footprints with regional access imperatives. By combining rigorous evidence generation, strategic partnerships, and adaptive logistics planning, organizations can position themselves to meet clinical demand effectively while also advancing the science of antithrombin therapeutics and diagnostics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Impact of recombinant antithrombin therapies on reducing postoperative thrombosis risk in cardiac surgery
  • 5.2. Evaluating global access barriers for recombinant antithrombin products in emerging healthcare markets
  • 5.3. Assessing economic impact of antithrombin deficiency screening programs on healthcare resource utilization
  • 5.4. Adoption trends of point of care antithrombin activity assays in critical care and emergency departments
  • 5.5. Regulatory harmonization challenges for multinational clinical trials involving recombinant antithrombin drugs
  • 5.6. Impact of SARS CoV 2 induced coagulopathy on antithrombin therapy demand and pricing strategies
  • 5.7. Integration of pharmacogenomic data for optimizing antithrombin replacement dosing in high risk thrombosis patients
  • 5.8. Long term safety and efficacy data shaping investor confidence in next generation antithrombin biosimilars

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Antithrombin Market, by Type

  • 8.1. Alpha
  • 8.2. Beta

9. Antithrombin Market, by Source

  • 9.1. Human Plasma
  • 9.2. Recombinant

10. Antithrombin Market, by Form

  • 10.1. Liquid
  • 10.2. Powder

11. Antithrombin Market, by Dosage Form

  • 11.1. Injectable
  • 11.2. Oral Suspensions

12. Antithrombin Market, by Therapeutic Application

  • 12.1. Acquired Deficiency
  • 12.2. Acute Pancreatitis
  • 12.3. Congenital Deficiency
  • 12.4. Disseminated Intravascular Coagulation
  • 12.5. Liver Disease
  • 12.6. Sepsis Associated Coagulopathy

13. Antithrombin Market, by End User

  • 13.1. Ambulatory Surgical Centers
  • 13.2. Clinics
  • 13.3. Diagnostic Laboratories
  • 13.4. Hospitals
  • 13.5. Research Institutes

14. Antithrombin Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Antithrombin Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Antithrombin Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Baxter International Inc.
    • 17.3.2. Bio-Techne Corporation
    • 17.3.3. Biocon Ltd.
    • 17.3.4. Boehringer Ingelheim Pharma GmbH & Co. KG
    • 17.3.5. China Biologic Products, Inc.
    • 17.3.6. Diapharma Group, Inc.
    • 17.3.7. European Medicines Agency
    • 17.3.8. F. Hoffmann-La Roche Ltd
    • 17.3.9. Genesis BioPharma Services
    • 17.3.10. Grifols, S.A.
    • 17.3.11. Jiangsu Hengrui Medicine Co., Ltd.
    • 17.3.12. Lee Biosolutions, Inc.
    • 17.3.13. LFB USA, Inc.
    • 17.3.14. Merck KGaA
    • 17.3.15. Novartis AG
    • 17.3.16. Octapharma AG
    • 17.3.17. Pfizer Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTITHROMBIN MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTITHROMBIN MARKET SIZE, BY TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ANTITHROMBIN MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ANTITHROMBIN MARKET SIZE, BY SOURCE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ANTITHROMBIN MARKET SIZE, BY SOURCE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTITHROMBIN MARKET SIZE, BY FORM, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ANTITHROMBIN MARKET SIZE, BY FORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANTITHROMBIN MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL ANTITHROMBIN MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ANTITHROMBIN MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS ANTITHROMBIN MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL ANTITHROMBIN MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. ANTITHROMBIN MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. ANTITHROMBIN MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ANTITHROMBIN MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ANTITHROMBIN MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ANTITHROMBIN MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ANTITHROMBIN MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTITHROMBIN MARKET SIZE, BY ALPHA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ANTITHROMBIN MARKET SIZE, BY ALPHA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTITHROMBIN MARKET SIZE, BY ALPHA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ANTITHROMBIN MARKET SIZE, BY ALPHA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTITHROMBIN MARKET SIZE, BY ALPHA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ANTITHROMBIN MARKET SIZE, BY ALPHA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTITHROMBIN MARKET SIZE, BY BETA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ANTITHROMBIN MARKET SIZE, BY BETA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTITHROMBIN MARKET SIZE, BY BETA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ANTITHROMBIN MARKET SIZE, BY BETA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTITHROMBIN MARKET SIZE, BY BETA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ANTITHROMBIN MARKET SIZE, BY BETA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ANTITHROMBIN MARKET SIZE, BY SOURCE, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTITHROMBIN MARKET SIZE, BY HUMAN PLASMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ANTITHROMBIN MARKET SIZE, BY HUMAN PLASMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTITHROMBIN MARKET SIZE, BY HUMAN PLASMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ANTITHROMBIN MARKET SIZE, BY HUMAN PLASMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTITHROMBIN MARKET SIZE, BY HUMAN PLASMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ANTITHROMBIN MARKET SIZE, BY HUMAN PLASMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTITHROMBIN MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ANTITHROMBIN MARKET SIZE, BY RECOMBINANT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTITHROMBIN MARKET SIZE, BY RECOMBINANT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ANTITHROMBIN MARKET SIZE, BY RECOMBINANT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTITHROMBIN MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ANTITHROMBIN MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ANTITHROMBIN MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTITHROMBIN MARKET SIZE, BY LIQUID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ANTITHROMBIN MARKET SIZE, BY LIQUID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTITHROMBIN MARKET SIZE, BY LIQUID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ANTITHROMBIN MARKET SIZE, BY LIQUID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTITHROMBIN MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ANTITHROMBIN MARKET SIZE, BY LIQUID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTITHROMBIN MARKET SIZE, BY POWDER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ANTITHROMBIN MARKET SIZE, BY POWDER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTITHROMBIN MARKET SIZE, BY POWDER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ANTITHROMBIN MARKET SIZE, BY POWDER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTITHROMBIN MARKET SIZE, BY POWDER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ANTITHROMBIN MARKET SIZE, BY POWDER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTITHROMBIN MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ANTITHROMBIN MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTITHROMBIN MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ANTITHROMBIN MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTITHROMBIN MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ANTITHROMBIN MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTITHROMBIN MARKET SIZE, BY ORAL SUSPENSIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ANTITHROMBIN MARKET SIZE, BY ORAL SUSPENSIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTITHROMBIN MARKET SIZE, BY ORAL SUSPENSIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ANTITHROMBIN MARKET SIZE, BY ORAL SUSPENSIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTITHROMBIN MARKET SIZE, BY ORAL SUSPENSIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ANTITHROMBIN MARKET SIZE, BY ORAL SUSPENSIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTITHROMBIN MARKET SIZE, BY ACQUIRED DEFICIENCY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ANTITHROMBIN MARKET SIZE, BY ACQUIRED DEFICIENCY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTITHROMBIN MARKET SIZE, BY ACQUIRED DEFICIENCY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ANTITHROMBIN MARKET SIZE, BY ACQUIRED DEFICIENCY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTITHROMBIN MARKET SIZE, BY ACQUIRED DEFICIENCY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ANTITHROMBIN MARKET SIZE, BY ACQUIRED DEFICIENCY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTITHROMBIN MARKET SIZE, BY ACUTE PANCREATITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ANTITHROMBIN MARKET SIZE, BY ACUTE PANCREATITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTITHROMBIN MARKET SIZE, BY ACUTE PANCREATITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ANTITHROMBIN MARKET SIZE, BY ACUTE PANCREATITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTITHROMBIN MARKET SIZE, BY ACUTE PANCREATITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ANTITHROMBIN MARKET SIZE, BY ACUTE PANCREATITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTITHROMBIN MARKET SIZE, BY CONGENITAL DEFICIENCY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ANTITHROMBIN MARKET SIZE, BY CONGENITAL DEFICIENCY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANTITHROMBIN MARKET SIZE, BY CONGENITAL DEFICIENCY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ANTITHROMBIN MARKET SIZE, BY CONGENITAL DEFICIENCY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANTITHROMBIN MARKET SIZE, BY CONGENITAL DEFICIENCY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ANTITHROMBIN MARKET SIZE, BY CONGENITAL DEFICIENCY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANTITHROMBIN MARKET SIZE, BY DISSEMINATED INTRAVASCULAR COAGULATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ANTITHROMBIN MARKET SIZE, BY DISSEMINATED INTRAVASCULAR COAGULATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANTITHROMBIN MARKET SIZE, BY DISSEMINATED INTRAVASCULAR COAGULATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ANTITHROMBIN MARKET SIZE, BY DISSEMINATED INTRAVASCULAR COAGULATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANTITHROMBIN MARKET SIZE, BY DISSEMINATED INTRAVASCULAR COAGULATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ANTITHROMBIN MARKET SIZE, BY DISSEMINATED INTRAVASCULAR COAGULATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANTITHROMBIN MARKET SIZE, BY LIVER DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ANTITHROMBIN MARKET SIZE, BY LIVER DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANTITHROMBIN MARKET SIZE, BY LIVER DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ANTITHROMBIN MARKET SIZE, BY LIVER DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANTITHROMBIN MARKET SIZE, BY LIVER DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ANTITHROMBIN MARKET SIZE, BY LIVER DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANTITHROMBIN MARKET SIZE, BY SEPSIS ASSOCIATED COAGULOPATHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ANTITHROMBIN MARKET SIZE, BY SEPSIS ASSOCIATED COAGULOPATHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANTITHROMBIN MARKET SIZE, BY SEPSIS ASSOCIATED COAGULOPATHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ANTITHROMBIN MARKET SIZE, BY SEPSIS ASSOCIATED COAGULOPATHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANTITHROMBIN MARKET SIZE, BY SEPSIS ASSOCIATED COAGULOPATHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ANTITHROMBIN MARKET SIZE, BY SEPSIS ASSOCIATED COAGULOPATHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ANTITHROMBIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANTITHROMBIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ANTITHROMBIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANTITHROMBIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ANTITHROMBIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANTITHROMBIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ANTITHROMBIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANTITHROMBIN MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ANTITHROMBIN MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ANTITHROMBIN MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ANTITHROMBIN MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ANTITHROMBIN MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ANTITHROMBIN MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ANTITHROMBIN MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ANTITHROMBIN MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ANTITHROMBIN MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ANTITHROMBIN MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ANTITHROMBIN MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ANTITHROMBIN MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ANTITHROMBIN MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ANTITHROMBIN MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ANTITHROMBIN MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ANTITHROMBIN MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ANTITHROMBIN MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ANTITHROMBIN MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ANTITHROMBIN MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ANTITHROMBIN MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ANTITHROMBIN MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ANTITHROMBIN MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ANTITHROMBIN MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ANTITHROMBIN MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ANTITHROMBIN MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ANTITHROMBIN MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. AMERICAS ANTITHROMBIN MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 134. AMERICAS ANTITHROMBIN MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 135. AMERICAS ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 136. AMERICAS ANTITHROMBIN MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 137. AMERICAS ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 138. AMERICAS ANTITHROMBIN MARKET SIZE, BY SOURCE, 2025-2032 (USD MILLION)
  • TABLE 139. AMERICAS ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 140. AMERICAS ANTITHROMBIN MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 141. AMERICAS ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 142. AMERICAS ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 143. AMERICAS ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 144. AMERICAS ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 145. AMERICAS ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS ANTITHROMBIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. NORTH AMERICA ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 150. NORTH AMERICA ANTITHROMBIN MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 152. NORTH AMERICA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2025-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 154. NORTH AMERICA ANTITHROMBIN MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 156. NORTH AMERICA ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 158. NORTH AMERICA ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 160. NORTH AMERICA ANTITHROMBIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. LATIN AMERICA ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 164. LATIN AMERICA ANTITHROMBIN MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 166. LATIN AMERICA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2025-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 168. LATIN AMERICA ANTITHROMBIN MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 170. LATIN AMERICA ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 172. LATIN AMERICA ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 174. LATIN AMERICA ANTITHROMBIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2025-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 189. EUROPE ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. EUROPE ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE ANTITHROMBIN MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE ANTITHROMBIN MARKET SIZE, BY SOURCE, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE ANTITHROMBIN MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE ANTITHROMBIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. MIDDLE EAST ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. MIDDLE EAST ANTITHROMBIN MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 208. MIDDLE EAST ANTITHROMBIN MARKET SIZE, BY SOURCE, 2025-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 210. MIDDLE EAST ANTITHROMBIN MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 212. MIDDLE EAST ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 214. MIDDLE EAST ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 216. MIDDLE EAST ANTITHROMBIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 217. AFRICA ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. AFRICA ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. AFRICA ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. AFRICA ANTITHROMBIN MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 221. AFRICA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 222. AFRICA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2025-2032 (USD MILLION)
  • TABLE 223. AFRICA ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 224. AFRICA ANTITHROMBIN MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 225. AFRICA ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 226. AFRICA ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 227. AFRICA ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 228. AFRICA ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 229. AFRICA ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 230. AFRICA ANTITHROMBIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC ANTITHROMBIN MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC ANTITHROMBIN MARKET SIZE, BY SOURCE, 2025-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC ANTITHROMBIN MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 239. ASIA-PACIFIC ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 240. ASIA-PACIFIC ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 242. ASIA-PACIFIC ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC ANTITHROMBIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL ANTITHROMBIN MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL ANTITHROMBIN MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. ASEAN ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. ASEAN ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. ASEAN ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. ASEAN ANTITHROMBIN MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 251. ASEAN ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 252. ASEAN ANTITHROMBIN MARKET SIZE, BY SOURCE, 2025-2032 (USD MILLION)
  • TABLE 253. ASEAN ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 254. ASEAN ANTITHROMBIN MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 255. ASEAN ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 256. ASEAN ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 257. ASEAN ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 258. ASEAN ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 259. ASEAN ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 260. ASEAN ANTITHROMBIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 261. GCC ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GCC ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GCC ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 264. GCC ANTITHROMBIN MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 265. GCC ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 266. GCC ANTITHROMBIN MARKET SIZE, BY SOURCE, 2025-2032 (USD MILLION)
  • TABLE 267. GCC ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 268. GCC ANTITHROMBIN MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 269. GCC ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 270. GCC ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 271. GCC ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 272. GCC ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 273. GCC ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 274. GCC ANTITHROMBIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPEAN UNION ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPEAN UNION ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPEAN UNION ANTITHROMBIN MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPEAN UNION ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPEAN UNION ANTITHROMBIN MARKET SIZE, BY SOURCE, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPEAN UNION ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPEAN UNION ANTITHROMBIN MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPEAN UNION ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPEAN UNION ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPEAN UNION ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPEAN UNION ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPEAN UNION ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPEAN UNION ANTITHROMBIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 289. BRICS ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. BRICS ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. BRICS ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 292. BRICS ANTITHROMBIN MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 293. BRICS ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 294. BRICS ANTITHROMBIN MARKET SIZE, BY SOURCE, 2025-2032 (USD MILLION)
  • TABLE 295. BRICS ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 296. BRICS ANTITHROMBIN MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 297. BRICS ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 298. BRICS ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 299. BRICS ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 300. BRICS ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 301. BRICS ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 302. BRICS ANTITHROMBIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 303. G7 ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 304. G7 ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 305. G7 ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 306. G7 ANTITHROMBIN MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 307. G7 ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 308. G7 ANTITHROMBIN MARKET SIZE, BY SOURCE, 2025-2032 (USD MILLION)
  • TABLE 309. G7 ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 310. G7 ANTITHROMBIN MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 311. G7 ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 312. G7 ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 313. G7 ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 314. G7 ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 315. G7 ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 316. G7 ANTITHROMBIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 317. NATO ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 318. NATO ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 319. NATO ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 320. NATO ANTITHROMBIN MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 321. NATO ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 322. NATO ANTITHROMBIN MARKET SIZE, BY SOURCE, 2025-2032 (USD MILLION)
  • TABLE 323. NATO ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 324. NATO ANTITHROMBIN MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 325. NATO ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 326. NATO ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 327. NATO ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 328. NATO ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 329. NATO ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 330. NATO ANTITHROMBIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 331. GLOBAL ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 332. GLOBAL ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 333. UNITED STATES ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 334. UNITED STATES ANTITHROMBIN MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 335. UNITED STATES ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 336. UNITED STATES ANTITHROMBIN MARKET SIZE, BY SOURCE, 2025-2032 (USD MILLION)
  • TABLE 337. UNITED STATES ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 338. UNITED STATES ANTITHROMBIN MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 339. UNITED STATES ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 340. UNITED STATES ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 341. UNITED STATES ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 342. UNITED STATES ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 343. UNITED STATES ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 344. UNITED STATES ANTITHROMBIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 345. CANADA ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 346. CANADA ANTITHROMBIN MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 347. CANADA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 348. CANADA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2025-2032 (USD MILLION)
  • TABLE 349. CANADA ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 350. CANADA ANTITHROMBIN MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 351. CANADA ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 352. CANADA ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 353. CANADA ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 354. CANADA ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 355. CANADA ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 356. CANADA ANTITHROMBIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 357. MEXICO ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 358. MEXICO ANTITHROMBIN MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 359. MEXICO ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 360. MEXICO ANTITHROMBIN MARKET SIZE, BY SOURCE, 2025-2032 (USD MILLION)
  • TABLE 361. MEXICO ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 362. MEXICO ANTITHROMBIN MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 363. MEXICO ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 364. MEXICO ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 365. MEXICO ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 366. MEXICO ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 367. MEXICO ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 368. MEXICO ANTITHROMBIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 369. BRAZIL ANTITHROMBIN MARKET SIZE, BY TYPE